Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 60 от 240

Набира участници

Trial of Orbital Atherectomy Versus Standard Strategy in Calcified Bifurcation Lesions

Coronary Artery Disease Coronary Disease

Clinical research with medical devices indicated in accordance with the CE marking, led by researchers, multicenter, open, prospective, randomized and controlled. Patients are randomized to treatment with a conventional balloon and then a coronary stent or to initial plaque modification with Orbital Atherectomy (OA) and then a coronary stent. To evaluate the efficacy and safety of OA in the adequate treatment with coronary stent of the calcified bifurcation lesion using angiography and optical coherence tomography (OCT).

Начало: 23.10.2025 Край: 31.12.2026 Възраст: от 18 г.

Spain Fundación EPIC NCT06736899

Набира участници Фаза 1

PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.

Liver Cancer

Evaluating the Safety and Efficacy of PD-1 mRNA LNP Vaccine Therapy in Patients with Primary Hepatocellular Carcinoma Who Have Failed Advanced Standard Therapy

Начало: 23.10.2025 Край: 30.12.2026 Възраст: 18–70 г.

China West China Hospital NCT07053072

Набира участници Фаза 1

A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

Haemophilia A

This study will test how different doses of study medicine (Inno8) work in the bodies of people with haemophilia A. The purpose of the study is to see if Inno8 is safe to use for people with haemophilia A. The study medicine is a new medicine that cannot yet be prescribed by doctors. The study will last for about 11 weeks.

Начало: 23.10.2025 Край: 05.02.2027 Възраст: 18–64 г.

Austria, Belgium, France +9 Novo Nordisk A/S NCT07220564

Набира участници Фаза 4

Got Doxy- 'Flipping the Script' on STI PEP

Sexually Transmitted Infections (STI)

This study is being done to test the effects of doxycycline on inflammation and the bacteria in the body in people with HIV and in people on HIV pre-exposure prophylaxis. This drug is approved by the Food and Drug Administration (FDA) for the treatment of bacterial infections. The study team will investigate whether the drug has additional effects on inflammation or on the bacteria that live in the body.

Начало: 22.10.2025 Край: 13.04.2029 Възраст: от 18 г.

United States Emory University NCT07215325

Набира участници Фаза 1

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Ovarian Neoplasms Breast Neoplasms Pancreatic Intraductal Neoplasms Colorectal Neoplasms +3

This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.

Начало: 22.10.2025 Край: 01.03.2033 Възраст: от 18 г.

Germany, Japan, Netherlands +1 Eli Lilly and Company NCT07213791

Набира участници Фаза 2

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Triple-Negative Breast Carcinoma

This phase II trial tests how well radiation therapy with pembrolizumab and chemotherapy (paclitaxel or nab-paclitaxel or carboplatin and gemcitabine) works in treating patients with PD-L1 positive triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Carboplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill cancer cells. High dose radiation therapy with pembrolizumab and chemotherapy may effective in treating patients with PD-L1 positive metastatic triple negative breast cancer.

Начало: 22.10.2025 Край: 13.02.2028 Възраст: от 18 г.

United States Emory University NCT06492759

Набира участници Фаза 2

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

Asthma

The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma. Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.

Начало: 22.10.2025 Край: 01.06.2028 Възраст: 18–75 г.

Argentina, Brazil, Canada +9 Eli Lilly and Company NCT07219173

Набира участници

A Clinical Trial Assessing the Safety and Effectiveness of the DurAVR® THV System

Severe Aortic Stenosis Valve-in-valve Procedures

Prospective, randomized, controlled, multicenter, international study. Up to 1054 subjects with a severe native calcific aortic stenosis who are determined by the local Heart Team to have an indication for Transcatheter Aortic Valve Replacement (TAVR), will be enrolled in the 'All Comers Randomized Cohort'. Subjects will be randomized 1:1 to receive either the DurAVR® THV System or any commercially available and approved Transcatheter Heart Valve (THV) from the SAPIEN series or the Evolut series and followed for 10 years. After completion of the All Comers Randomized Cohort, up to 446 additional low-risk subjects will be randomized 1:1 in the 'Low Risk Randomized Continued Access Cohort'. Up to 150 subjects with a failed surgical bioprosthesis who are deemed high surgical risk and who need valve-in-valve (ViV) TAVR will be enrolled in a separate nested registry (ViV Registry Cohort) and followed for 5 years. Subjects in the ViV Registry Cohort will only receive the DurAVR® THV.

Начало: 21.10.2025 Край: 01.03.2038 Възраст: от 18 г.

Denmark Anteris Technologies Ltd. NCT07194265

Набира участници

Patient Navigation and the Planning Advance Care Together Website to Improve Goals of Care Conversations in Hematopoietic Cell Transplant Survivors, IMPACT-HCT Trial

Hematopoietic and Lymphatic System Neoplasm

This clinical trial evaluates the impact of patient navigation and the Planning Advance Care Together (PACT) website, either alone or in combination with one another, on advanced care planning (ACP) in patients with blood cancers who received a hematopoietic cell transplant (HCT). Engagement in ACP, including having goals of care conversations, improves quality of care at the end of life and supporting this should be included in all cancer survivorship care. Patient navigation is a healthcare service that is designed to guide a patient through the healthcare system and reduce barriers to timely screening follow-up, diagnosis, treatment, and supportive care. PACT is a web-based tool that provides information about ACP, assistance with documents for advanced directives, a supportive network and a forum for discussions about ACP. Patients who engage in ACP are more likely to have higher quality of life at the end of life, receive the care they want, die where they prefer, utilize hospice effectively, and are less likely to receive futile, aggressive care at the end of life. For HCT survivors at ongoing risk of death and other disease-related complications, having a plan in place for care they want is critical. Patient navigation and/or the PACT website may improve ACP, including completion of advance care directives and goals of care conversations, in patients with blood cancers who received an HCT.

Начало: 21.10.2025 Край: 31.07.2026 Възраст: от 18 г.

United States Fred Hutchinson Cancer Center NCT07052630

Набира участници

Subcision With Injection of Poly Deoxyribonucleotide Versus Subcision With Injection of Non-cross Linked Hyaluronic Acid in Rolling Acne Scars Treatment : A Split Face Randomized Controlled Clinical Trial

Rolling Acne Scars

The aim of this study is to evaluate and compare the efficacy and safety of two different injectable agents combined with subcision for treating rolling acne scars. In this split-face clinical trial, each participant will receive subcision on both sides of the face. One side will then be treated with an injection of Polydeoxyribonucleotide (PDRN), while the other side will receive an injection of non-cross linked Hyaluronic acid (HA). The clinical outcomes and improvement in scar appearance will be assessed and compared between both treatments

Начало: 20.10.2025 Край: 20.07.2026 Възраст: от 18 г.

Egypt Cairo University NCT07547956

Набира участници

Children's Health, Respiratory Inflammation and Short-term Air Pollution

Asthma Acute Respiratory

The goal of this study is to see if physical activity in high air pollution is worse than rest in high air pollution.

Начало: 20.10.2025 Край: 01.07.2027 Възраст: 7–11 г.

United Kingdom Queen Mary University of London NCT07431021

Набира участници Фаза 2/3

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia (ITP) ITP - Immune Thrombocytopenia ITP Immune Thrombocytopenic Purpura +3

The main purpose of this study is to confirm the correct dose of efgartigimod IV for treating patients aged 12 to younger than 18 years with chronic immune thrombocytopenia (ITP). The study consists of a double-blinded treatment period (DBTP) in which the participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV. At the end of the treatment period (up to 24 weeks), all participants will receive efgartigimod IV during the first year open-label treatment period (OLTP1). At the end of the first OLTP1, participants may begin a second year (OLTP2). After the OLTP2, the participants will enter a follow-up period (approximately 8 weeks) while off study drug. The participants will be in the study for up to 138 weeks. More information can be found here: https://clinicaltrials.argenx.com/advancejunior

Начало: 20.10.2025 Край: 01.10.2030 Възраст: 12–17 г.

Italy, Poland, Romania +2 argenx NCT07194850

Набира участници

Comparison of Analgesic Efficacy of Suprainguinal Fascia Iliaca and Quadro-iliac Blocks in Hip Fracture Surgery

Post Operative Pain

Hip fractures are common in the elderly and are associated with significant morbidity and mortality. Effective early analgesia is crucial for facilitating mobilization, reducing pulmonary complications, and improving overall outcomes. Although opioids are traditionally used for postoperative pain management, their adverse effects have led to increased interest in multimodal analgesia, particularly peripheral nerve blocks. The suprainguinal fascia iliaca block (SIFI) is a modified technique that allows wider spread of local anesthetic, providing more effective blockade of the femoral, obturator, and lateral femoral cutaneous nerves. The quadro-iliac plane block (QIPB), a recently described interfascial block, is performed at the level of the anterior superior iliac spine and may also affect branches of the lumbar and sacral plexus. While both techniques have been shown to provide effective analgesia and reduce opioid consumption, there is no study directly comparing them. Therefore, this study aims to compare the postoperative analgesic efficacy of SIFI and QIPB in patients undergoing hip fracture surgery.

Начало: 20.10.2025 Край: 15.06.2026 Възраст: от 18 г.

Turkey (Türkiye) Hitit University NCT07546903

Набира участници

PREDICTORS OF FUNCTIONAL STATUS IN CHRONIC NECK PAIN

Neck Pain

Although it has been reported that these problems seen together with neck pain are related to functional limitations and disability, there is still insufficient evidence regarding the relationship between factors affecting functional status and chronic neck pain symptoms in individuals with chronic neck pain. Furthermore, a mixed methodology approach has not been used to comprehensively investigate this relationship. Identifying factors affecting functional status in CNP will help guide the prevention, treatment, and management of neck pain. Therefore, the aim of this study is to investigate the relationships between functional status and psychosocial and bodily functions in CNP.

Начало: 20.10.2025 Край: 20.06.2026 Възраст: 18–65 г.

Turkey (Türkiye) Kutahya Health Sciences University NCT07544108

Набира участници Фаза 2

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

Atrial Fibrillation (AF)

This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the study is to see how well REGN7508 and REGN9933 work in patients that get medicine for their atrial fibrillation. The bleeding effects of REGN7508 and REGN9933 will be compared to another medicine (apixaban), which is available on the market to treat and prevent formation of blood clots. The study is looking at several other research questions, including: * What side effects may happen from taking REGN7508 or REGN9933 * How well do the study drugs reduce the risk of having a stroke * How much of REGN7508 or REGN9933 is in the blood at different times * Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the drugs less effective or could lead to side effects)

Начало: 20.10.2025 Край: 21.04.2027 Възраст: от 18 г.

Canada, United States Regeneron Pharmaceuticals NCT07175428

Набира участници

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

Clonal Mast Cell Disease KIT D816V Mutation Suspected KITD816V Mutated Clonal Mast Cell Disease

This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.

Начало: 17.10.2025 Край: 31.10.2028 Възраст: от 18 г.

United States Blueprint Medicines Corporation NCT07143669

Набира участници Фаза 3

A Study of Brenipatide in Participants With Alcohol Use Disorder

Alcohol Use Disorder

The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with Alcohol Use Disorder (AUD) and hazardous alcohol use. Participation in this study will last approximately 56 weeks.

Начало: 16.10.2025 Край: 01.04.2028 Възраст: 18–75 г.

Belgium, China, Germany +5 Eli Lilly and Company NCT07219953

Набира участници

PACT Involvement in Cardiology Patients

Machine Learning Cardiovascular Outcome Pediatric Palliative Care Pediatric Cardiology

The goal of this trial is to determine the effectiveness of a machine-learning (ML) model predicting a serious cardiac event within the next three months, when compared pre- versus post-deployment, in pediatric cardiac inpatients. The main questions it aims to answer are whether deployment of the ML model: 1. Increases PACT consultation within the next three months among admissions without PACT involvement in the previous 100 days 2. Increases PACT consultation or visit within the next three months among those who experience a serious cardiac event during this period 3. Decreases time to PACT consultation or visit among those seen by PACT during this period 4. Decreases the incidence of death in the intensive care unit (ICU) 5. Increases documentation of goals of care High-risk cardiology patients will be identified by an ML model each morning. If the patient has been seen by the PACT team within the past year, the update will go to the PACT team members. If the patient hasn't been seen by the PACT team, the email will be sent to the cardiology physician in charge of the patient. This physician will decide whether a PACT consultation is necessary based on their clinical judgment. If so, a referral will be made using the usual process. Outcomes of the identified patients will be compared pre- and post-deployment.

Начало: 16.10.2025 Край: 16.10.2027 Възраст: до 18 г.

Canada The Hospital for Sick Children NCT06886529

Набира участници

Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue

Skin Laxity (Submental and Neck) Facial Skin Laxity Submental Tissue Laxity

This is a prospective, multicenter, randomized, evaluator-blinded, parallel-controlled, non-inferiority clinical study designed to evaluate the safety and effectiveness of the ULTRAFORMER MPT PLUS, a high-intensity focused ultrasound (HIFU) device, for lifting and tightening lax submental (beneath the chin) and neck tissue in adult subjects. Approximately 273 subjects will be enrolled at multiple investigational sites across the United States. Participants will receive either the ULTRAFORMER MPT PLUS treatment or the predicate comparator device, and will be followed for safety and efficacy assessments including clinical photography, investigator evaluation, and patient-reported outcomes. The study aims to demonstrate that ULTRAFORMER MPT PLUS is non-inferior to the approved reference device in improving skin laxity and wrinkle appearance of the lower face and neck.

Начало: 16.10.2025 Край: 26.11.2026 Възраст: 30–65 г.

United States CLASSYS Inc. NCT07229430

Набира участници

The Effect of Stress Ball on Nausea, Anxiety, and Fatigue in Patients With Stomach Cancer

Stomach Cancer Chemotherapy-induced Nausea and Vomiting Fatigue

In this study, we will observe the effects of the Stress Ball.

Начало: 15.10.2025 Край: 24.05.2026 Възраст: 18–80 г.

Turkey (Türkiye) Yuzuncu Yil University NCT07540169

1 … 58 59 60 61 62 … 240